Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation [PDF]
Journal of Pharmaceutical Analysis, 2023 Given that impurities may affect the quality and safety of drug products, impurity identification and profiling is an integral part of drug quality control and is particularly important for newly developed medications such as solriamfetol, which is used ...
Nafisah M Al-Rifai, lena shaghlil
exaly +7 more sources
Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system. [PDF]
PLoS ONEPurposeExcessive daytime sleepiness (EDS) seriously affects quality of life and may increase the risk of life-threatening situations, such as motor vehicle accidents.
Lingling Wu, Kaijian Zhu
doaj +3 more sources
A randomized study of solriamfetol for excessive sleepiness in narcolepsy [PDF]
Annals of Neurology, 2019 Objective: Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.
Colin Shapiro +2 more
exaly +7 more sources
Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial [PDF]
Frontiers in MedicineIntroductionWake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA).
Fen Wang +7 more
doaj +3 more sources
Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database [PDF]
Frontiers in PharmacologyObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou +5 more
doaj +3 more sources
Solriamfetol enhances alertness and cognitive performance in mice
bioRxivAbstractSolriamfetol [(R)-2-amino-3-phenylpropylcarbamate hydrochloride], a phenylalanine derivative initially developed as potential antidepressant, was shown by our group in 2009 to have potent, dose-dependent wake-promoting activity in mice. Solriamfetol (Sunosi®) is used since 2019 to counteract excessive daytime sleepiness (EDS) in patients with ...
Haddar M +4 more
europepmc +3 more sources
A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness. [PDF]
Psychopharmacol BullPurpose of Review This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this ...
Fuller MC +10 more
europepmc +4 more sources
Pharmacological and non-pharmacological methods of inducing wakefulness activate distinct neural populations in the mouse brain. [PDF]
PLoS BiologyA large body of data indicate that the aminergic, cholinergic and hypocretin/orexin neurons are responsible for inducing wakefulness. However, recent data showed that other systems might also play a key role.
Renato Maciel +8 more
doaj +2 more sources
Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis [PDF]
BMC NeurologyBackground As a rare sleep disorder, narcolepsy is treated with various therapeutic options. This article systematically analyzes the efficacy and safety of novel approved wake-promoting drugs.
Zian Yan +5 more
doaj +2 more sources
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis [PDF]
Nature and Science of Sleep, 2023 Shuqin Zhan,1 Hui Ye,2 Ning Li,1 Yimeng Zhang,1 Yueyang Cheng,1 Yuanqing Wang,1,3 Shimin Hu,1 Yue Hou1 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China; 2Ignis Therapeutics (Shanghai ...
Zhan S +7 more
doaj +2 more sources